InhibinB as a Marker for Premenstrual Dysphoric Symptoms

抑制素 B 作为经前烦躁症状的标志物

• 批准号: 7099094
• 负责人: SHIRLEY ANN HARTLAGE
• 金额: $ 27.46万
• 依托单位: RUSH UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-06-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7099094
• 关键词: African American; Hispanic Americans; age difference; biomarker; blood chemistry; body composition; caucasian American; clinical depression; clinical research; diagnosis design /evaluation; diagnostic tests; emotional adjustment; enzyme linked immunosorbent assay; female; follicle stimulating hormone; hormone regulation /control mechanism; inhibin; menstrual cycle; mental disorder diagnosis; ovary; patient oriented research; premenstrual syndrome; racial /ethnic difference; women' s health

DESCRIPTION (provided by applicant): The broad, long-term objective of the proposed research is to find the causes of severe premenstrual mood and behavior changes, facilitate diagnosis, and speed effective treatment to women seeking help for related disorders. For decades scientists have worked to identify characteristics of the ovarian axis that are associated with premenstrual disorders. Now, results from state-of-the-art endocrine research, the body of knowledge about premenstrual dysphoric disorder (PMDD), and our pilot study converge to suggest that inhibin B, a new marker of ovarian function, may be a biomarker of PMDD. The Specific Aims are to explore (1) the relationship of inhibin B and PMDD; and (2) to determine whether inhibin B differentiates women with and without PMDD after potential confounders are taken into account (the Aberrant Inhibin B Model). Hypotheses will be examined in a sample of 18 to 53-year-old Hispanic, Black, or White menstruating women with or without PMDD (N = 102). To diagnose PMDD according to DSM criteria, participants will rate symptoms and functioning daily for two menstrual cycles, and complete physical and psychiatric evaluations. In each cycle, participants will give blood samples every 3 days after the onset of menstruation until ovulation occurs as determined by home urinary luteinizing hormone test kits. Inhibin B levels will be measured in serum using ELISA. If inhibin B is a marker of PMDD, this may provide clues to the mechanisms of the disorder, premenstrual exacerbations of other conditions, and emotional reactivity in general. Laboratory studies of inhibin B already have been translated into practice aiding diagnosis of various reproductive conditions. Results of this and subsequent studies may facilitate diagnosis of PMDD. New medications targeting endocrine risk factors for premenstrual disorders ultimately may be discovered. The medications may be more efficacious, and more acceptable to women not wanting antidepressants. Data from minorities and perimenopausal women should help scientists address health disparities. Premenstrual dysphoric disorder (PMDD) is one of the most common conditions affecting reproductive age women having a high impact on personal well-being and professional productivity. This study explores the relationship of inhibin B, a new marker of ovarian function, and PMDD. Results are expected to provide clues to the cause of PMDD, facilitate the now burdensome diagnostic process, and lead to new treatments.

描述（由申请人提供）：拟议研究的广泛、长期目标是找到严重经前情绪和行为变化的原因，促进诊断，并加快对寻求相关疾病帮助的女性的有效治疗。几十年来，科学家们一直致力于确定与经前疾病相关的卵巢轴特征。现在，最先进的内分泌研究结果、有关经前烦躁症 (PMDD) 的知识体系以及我们的试点研究汇聚在一起表明，抑制素 B（卵巢功能的新标志物）可能是经前烦躁症的生物标志物。具体目标是探讨（1）抑制素B与经前抑郁症（PMDD）的关系； (2) 在考虑潜在的混杂因素后，确定抑制素 B 是否能够区分患有和不患有经前抑郁症的女性（异常抑制素 B 模型）。假设将在患有或不患有经前抑郁症 (PMDD) 的 18 至 53 岁西班牙裔、黑人或白人经期女性样本中进行检验 (N = 102)。为了根据 DSM 标准诊断经前抑郁症，参与者将在两个月经周期中每天对症状和功能进行评分，并完成身体和精神评估。在每个周期中，参与者将在月经开始后每 3 天采集一次血液样本，直到通过家用尿液黄体生成素检测试剂盒确定排卵为止。使用 ELISA 测量血清中的抑制素 B 水平。如果抑制素 B 是经前抑郁症的标志物，这可能会为该疾病的机制、其他病症的经前恶化以及一般情绪反应提供线索。抑制素 B 的实验室研究已转化为实践，帮助诊断各种生殖状况。这项研究和后续研究的结果可能有助于 PMDD 的诊断。最终可能会发现针对经前疾病内分泌危险因素的新药物。这些药物可能更有效，并且更容易被不需要抗抑郁药的女性接受。来自少数族裔和围绝经期妇女的数据应该有助于科学家解决健康差异问题。经前焦虑症 (PMDD) 是影响育龄妇女的最常见疾病之一，对个人福祉和职业生产力影响很大。本研究探讨了卵巢功能新标志物抑制素 B 与经前抑郁症 (PMDD) 的关系。研究结果有望为经前抑郁症的病因提供线索，促进目前繁重的诊断过程，并带来新的治疗方法。